You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Claims for Patent: 10,456,464

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,456,464

Title:	Liquid immunity induction-promoting composition and vaccine pharmaceutical composition that include thrombosis treatment drug
Abstract:	The present invention aims to provide a humoral immunity induction-promoting composition and a vaccine pharmaceutical composition which can universally be used for inducing humoral immunity to various antigens and exert a high antibody production inducing effect. The present invention relates to a vaccine pharmaceutical composition for inducing humoral immunity containing an antigen and a humoral immunity induction promoter whose active ingredient is a thrombosis treatment drug.
Inventor(s):	Shishido; Takuya (Osaka, JP), Asari; Daisuke (Osaka, JP), Matsushita; Kyohei (Osaka, JP), Hori; Mitsuhiko (Osaka, JP)
Assignee:	NITTO DENKO CORPORATION (Osaka, JP)
Application Number:	15/501,339
Patent Claims:	1. A vaccine pharmaceutical composition for inducing humoral immunity, comprising: an infectious pathogen-derived antigen in an amount of 0.000001 to 50% by weight based on a total weight of the vaccine pharmaceutical composition; and a humoral immunity induction-promoting composition comprising a humoral immunity induction promoter whose active ingredient is a thrombosis treatment drug, wherein the humoral immunity induction promoter is present in an amount of 0.001 to 10,000 parts by weight based on 1 part by weight of the antigen; wherein the infectious pathogen is selected from adenovirus, herpesvirus, picornavirus, poxvirus, picornavirus, orthomyxovirus, paramyxovirus, parvovirus, togavirus, coronavirus, hepadnavirus, flavivirus, hepevirus, papillomavirus, calicivirus, rhabdovirus, filovirus, arenavirus, bunyavirus, reovirus, retrovirus, Escherichia, Enterobacter, Salmonella, Staphylococcus, Shigella, Listeria, Aerobacter, Helicobacter, Klebsiella, Proteus, Pseudomonas, Streptococcus, Chlamydia, Mycoplasma, Pneumococci, Clostridium, Bacillus, Corynebacterium, Mycobacterium, Campyrobacter, Vibrio, Serratia, Providencia, Chromobacterium, Brucella, Yersinia, Haemophilus, Bordetella, and pathogens that cause chlamydia, candidiasis, aspergillosis, histoplasmosis, cryptococcal meningitis, malaria, pneumocystis carinii pneumonia, leishmaniasis, cryptosporidiosis, toxoplasmosis, and Trypanosoma infection; and wherein the thrombosis treatment drug is a thrombogenesis-suppressing compound that is at least one of an anticoagulant or an antiplatelet, the anticoagulant being at least one selected from the group consisting of fondaparinux, rivaroxaban, apixaban, edoxaban, betrixaban, eribaxaban, ximelagatran, dabigatran, argatroban, hirudin, nafamostat, camostat, gabexate, and warfarin, and the antiplatelet being at least one selected from the group consisting of abciximab, eptifibatide, and tirofiban. 2. The vaccine pharmaceutical composition according to claim 1, wherein the composition is formulated to be administered to a body surface. 3. The vaccine pharmaceutical composition according to claim 1, wherein the composition is formulated to be administered by intradermal injection, subcutaneous injection, or intramuscular injection. 4. The vaccine pharmaceutical composition according to claim 1, wherein the infectious pathogen is influenza. 5. The vaccine pharmaceutical composition according to claim 1, wherein the infectious pathogen-derived antigen is selected from H1N1, H3N2, Influenza B virus, Influenza B virus, pneumococcal capsular polysaccharide, HPV16 recombinant protein, live attenuated rotavirus, inactivated poliovirus, inactivated hepatitis A virus, inactivated Japanese encephalitis virus, live attenuated mumps virus, live attenuated measles virus, live attenuated rubella virus, tetanus toxoid-conjugated haemophilus influenzae type b polysaccharide, recombinant HBs antigen protein, live attenuated yellow fever virus, tetanus toxoid, live attenuated varicella virus, live BCG, and inactivated rabies virus. 6. The vaccine pharmaceutical composition according to claim 5, wherein the thrombosis treatment drug is selected from argatroban, nafamostat mesylate, camostat mesylate, and tirofiban. 7. A vaccine pharmaceutical composition for inducing humoral immunity, comprising: an infectious pathogen-derived antigen; and a humoral immunity induction-promoting composition comprising argatroban.

Details for Patent 10,456,464

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994	⤷ Try a Trial	2034-08-04
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.